Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment (RIPAT)

11 de junio de 2014 actualizado por: Martin Ortler, MD MSc, Medical University Innsbruck

The Role of Remote Ischemic Preconditioning in the Prevention of Ischemic Brain Damage During Intracranial Aneurysm Treatment (RIPAT) - A Prospective Randomized Exploratory Study

The RIPAT study is a prospective, randomized, double-blind study organized by the neurovascular group of the Clinical Department of Neurosurgery of Innsbruck Medical University, Innsbruck, Austria. Patients aged 18+ in whom the treatment of an un-ruptured intracranial aneurysm is indicated are eligible for study participation. Prior to aneurysm treatment, with the patient already under general anesthesia, the blood supply to an arm will be restricted for 3x 5minutes by inflating a standard blood pressure cuff. The study hypothesis is that this "remote ischemic preconditioning" maneuver is able to prevent a stroke during the following treatment of the aneurysm.

Descripción general del estudio

Descripción detallada

Prospective, randomized, double-blind, explorative single center clinical trial in patients subjected to the treatment of an un-ruptured intracranial aneurysm, either by surgical clipping or endovascular coiling. Goal of the study is to determine whether remote ischemic preconditioning (RIPC) prior to aneurysm treatment alters various biomarkers associated with ischemic central neuronal tissue damage. The trial takes place at Innsbruck University Hospital of Innsbruck Medical University, Innsbruck, Austria.

Patients fulfilling inclusion criteria are randomly allocated either to pre-interventional ischemic preconditioning (Group A = intervention group) or sham preconditioning (Group B = control group). RIPC is performed by inflating a blood pressure cuff around one upper extremity three times for five minutes with five minutes interval with the patient under general anesthesia prior to the start of the procedure.

Patients, all staff involved in diagnosis and treatment and all study members are blinded to the patients' group affiliation. The anesthesiologist and two staff members who perform preconditioning are not blinded.

Primary outcome is a difference of ± 2SD in the concentration-time curve of a panel of biochemical parameters indicative of cerebral ischemia (S100B, NSE, GFAP, MMP9, MBP, microparticles) in the first five days after the intervention. Secondary outcome parameters are changes in the post-interventional MRI and neuropsychological and clinical outcome at six and 12 months.

CONSORT and TIDieR guidelines will be followed. The trail will be registered in a public database. The trail protocol will be published in an open-access journal.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

48

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Innsbruck, Austria, 6020
        • Reclutamiento
        • Clinical Department of Neurosurgery, Innsbruck Medical University
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Martin Ortler, MD, MSc
        • Sub-Investigador:
          • Claudius Thomé, M.D.
        • Sub-Investigador:
          • Selma Tülü, Cand.med.
        • Sub-Investigador:
          • Miriam Mulino, M.D.
        • Sub-Investigador:
          • Daniel Pinggera, M.D.
        • Sub-Investigador:
          • Claudia Unterhofer, M.D.
        • Sub-Investigador:
          • Erich Schmutzhard, M.D.
        • Sub-Investigador:
          • Bettina Pfausler, M.D.
        • Sub-Investigador:
          • Ronny Beer, M.D.
        • Sub-Investigador:
          • Raimund Helbok, M.D.
        • Sub-Investigador:
          • Peter Lackner, M.D.
        • Sub-Investigador:
          • Thomas Benke, M.D.
        • Sub-Investigador:
          • Thomas Bodner, M.D.
        • Sub-Investigador:
          • Margarethe Delazer, M.D.
        • Sub-Investigador:
          • Raffaella Matteucci-Gothe, Ph.D.
        • Sub-Investigador:
          • Uwe Siewert, Ph.D.
        • Sub-Investigador:
          • Philipp Würtinger, M.D.
        • Sub-Investigador:
          • Andrea Griesmacher, M.D.
        • Sub-Investigador:
          • Markus Luger, M.D.
        • Sub-Investigador:
          • Arnulf Benzer, M.D.
        • Sub-Investigador:
          • Franz Wiedermann, M.D.
        • Sub-Investigador:
          • Astrid Grams, M.D.
        • Sub-Investigador:
          • Elke Gizewski, M.D.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Informed written consent of patient
  • Age > 18 years
  • Intracranial aneurysm, single or multiple, intervention as indicated by interdisciplinary vascular board (includes previously treated aneurysms)
  • Normal baseline MRI

Exclusion Criteria:

  • Clinical or radiological signs of subarachnoid hemorrhage
  • Planned vessel sacrifice as the primary modality for aneurysm treatment
  • Dissecting or mycotic aneurysm
  • Previous history of stroke or TIA within the last six months
  • Signs or symptoms of upper and lower extremity peripheral vascular illness
  • Drugs and lifestyle factors that interfere with biomarker Determination
  • Inability to complete neuropsychological testing for language reasons
  • Patients unable to have an MRI scan for any reason
  • Previous serious cerebral disease that would preclude completion of the protocol or preclude MRI analysis of small strokes
  • Pregnancy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Remote ischemic preconditioning
Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
Comparador falso: Sham preconditioning
Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area-under-Curve for biomarkers in the first 5 days after aneurysm treatment(S100B, NSE, GFAP, NSE, MMP9, Microparticles)
Periodo de tiempo: on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention
Serum biomarkers reflect brain tissue ischemic damage with various specificity and sensitivity (see Whiteley 2008, Ahmad 2012) Advantages include (1) to be available early, (2) to be continuous variables (low study n), (3) they were able to demonstrate an effect of ischemic preconditioning in other clinical studies (see Koch 2010, Veighei 2012)
on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number (n) of new lesions in postinterventional MRI (DWI and FLAIR)
Periodo de tiempo: preinterventional/on day 1 or 2
Outcome Parameter used in other clinical studies focussing on ischemia after neurointerventional procedures (e.g. ENACT study)
preinterventional/on day 1 or 2
Clinical outcome ( National Institutes of Health Stroke Scale, NIHSS and modified Rankin Scale mRS)
Periodo de tiempo: at discharge, at 6 and 12 months
Established outcome parameters for cerebrovascular studies. Dichotomized into favourable (NIHSS ≤1, mRS 0-1) and unfavourable
at discharge, at 6 and 12 months
Volume (mm3) of new lesions in postinterventional MRI (DWI and FLAIR)
Periodo de tiempo: preinterventional, postinterventional on day 1 or 2
As above for number of lesions
preinterventional, postinterventional on day 1 or 2

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Neuropsychological testing VLMTA (Verbaler Lern- und Merkfähigkeitstest), the WMS-R (Zahlenspanne vorwärts und rückwärts), trail making A and B tests, the Regensburger Wortflüssigkeitstest, the TAP Wechsel verbal, the TAP and the HADS-D)
Periodo de tiempo: preinterventional, at 6 and 12 months
Standard tests used in patients with cerebrovascular disorders in our departments. Not applicable to non-german-speaking patients.
preinterventional, at 6 and 12 months
Brain volume changes (MRI, voxel -based morphometry)
Periodo de tiempo: Preinterventional/at the 12 months FU
Longterm brain volume changes that correlate with NP deficits (Horstmann 2010, Moskowitz 2011, Vuylsteke 2011) will be analyzed using voxel-based morphometry techniques
Preinterventional/at the 12 months FU

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Martin Ortler, M.D., MSc., Clinical Department of Neurosurgery, Innsbruck Medical University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de noviembre de 2013

Finalización primaria (Anticipado)

1 de noviembre de 2015

Finalización del estudio (Anticipado)

1 de noviembre de 2016

Fechas de registro del estudio

Enviado por primera vez

10 de junio de 2014

Primero enviado que cumplió con los criterios de control de calidad

11 de junio de 2014

Publicado por primera vez (Estimar)

13 de junio de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

13 de junio de 2014

Última actualización enviada que cumplió con los criterios de control de calidad

11 de junio de 2014

Última verificación

1 de junio de 2014

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir